Nephron Sterile Compounding Center is recalling approximately 3,840 bags of Fentanyl Citrate, Bupivacaine, and Ropivacaine injections due to potential glass contamination and manufacturing deviations. These prescription pain management medications, including PF-Fentanyl Citrate with Bupivacaine HCl and PF-Fentanyl Citrate with Ropivacaine HCl, were distributed in 200 mL and 250 mL bags. The defect was discovered during a quality review that identified risks of glass fragments entering the sterile solutions.
Injecting a product containing glass fragments can cause serious health consequences, including local irritation, inflammation, or more severe issues if the glass travels through the blood vessels to vital organs. No injuries have been reported to date, but the presence of particulate matter in sterile injections poses a significant risk of internal damage or blockage of blood flow.
Healthcare provider consultation and product return.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.